Copyright Reports & Markets. All rights reserved.

Global Recombinant Non-Glycosylated Proteins Biosimilars Market Research Report 2019

Request for Sample of this report
Buy now
  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Recombinant Non-Glycosylated Proteins Biosimilars Industry
  • 1.7 COVID-19 Impact: Recombinant Non-Glycosylated Proteins Biosimilars Market Trends

    • 2 Global Recombinant Non-Glycosylated Proteins Biosimilars Quarterly Market Size Analysis

    • 2.1 Recombinant Non-Glycosylated Proteins Biosimilars Business Impact Assessment - COVID-19
      • 2.1.1 Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Recombinant Non-Glycosylated Proteins Biosimilars Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 By Players, Global Recombinant Non-Glycosylated Proteins Biosimilars Quarterly Market Size, 2019 VS 2020
    • 3.2 By Players, Recombinant Non-Glycosylated Proteins Biosimilars Headquarters and Area Served
    • 3.3 Date of Key Players Enter into Recombinant Non-Glycosylated Proteins Biosimilars Market
    • 3.4 Key Players Recombinant Non-Glycosylated Proteins Biosimilars Product Offered
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Recombinant Non-Glycosylated Proteins Biosimilars Segments, By Type

    • 4.1 Introduction
      • 1.4.1 Insulin
      • 1.4.2 rHGH
      • 1.4.3 Interferon
    • 4.2 By Type, Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size, 2019-2021

    5 Impact of Covid-19 on Recombinant Non-Glycosylated Proteins Biosimilars Segments, By Application

    • 5.1 Overview
      • 5.5.1 Oncology
      • 5.5.2 Chronic Diseases
      • 5.5.3 Autoimmune Diseases
      • 5.5.4 Blood Disorders
      • 5.5.5 Growth Hormone Deficiency
      • 5.5.6 Infectious Diseases
      • 5.5.7 Other Diseases
    • 5.2 By Application, Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size, 2019-2021
      • 5.2.1 By Application, Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application, 2019-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 Sandoz
      • 7.1.1 Sandoz Business Overview
      • 7.1.2 Sandoz Recombinant Non-Glycosylated Proteins Biosimilars Quarterly Revenue, 2020
      • 7.1.3 Sandoz Recombinant Non-Glycosylated Proteins Biosimilars Product Introduction
      • 7.1.4 Sandoz Response to COVID-19 and Related Developments
    • 7.2 Pfizer
      • 7.2.1 Pfizer Business Overview
      • 7.2.2 Pfizer Recombinant Non-Glycosylated Proteins Biosimilars Quarterly Revenue, 2020
      • 7.2.3 Pfizer Recombinant Non-Glycosylated Proteins Biosimilars Product Introduction
      • 7.2.4 Pfizer Response to COVID-19 and Related Developments
    • 7.3 Teva Pahrmaceutical
      • 7.3.1 Teva Pahrmaceutical Business Overview
      • 7.3.2 Teva Pahrmaceutical Recombinant Non-Glycosylated Proteins Biosimilars Quarterly Revenue, 2020
      • 7.3.3 Teva Pahrmaceutical Recombinant Non-Glycosylated Proteins Biosimilars Product Introduction
      • 7.3.4 Teva Pahrmaceutical Response to COVID-19 and Related Developments
    • 7.4 Celltrion
      • 7.4.1 Celltrion Business Overview
      • 7.4.2 Celltrion Recombinant Non-Glycosylated Proteins Biosimilars Quarterly Revenue, 2020
      • 7.4.3 Celltrion Recombinant Non-Glycosylated Proteins Biosimilars Product Introduction
      • 7.4.4 Celltrion Response to COVID-19 and Related Developments
    • 7.5 Biocon
      • 7.5.1 Biocon Business Overview
      • 7.5.2 Biocon Recombinant Non-Glycosylated Proteins Biosimilars Quarterly Revenue, 2020
      • 7.5.3 Biocon Recombinant Non-Glycosylated Proteins Biosimilars Product Introduction
      • 7.5.4 Biocon Response to COVID-19 and Related Developments
    • 7.6 Amgen
      • 7.6.1 Amgen Business Overview
      • 7.6.2 Amgen Recombinant Non-Glycosylated Proteins Biosimilars Quarterly Revenue, 2020
      • 7.6.3 Amgen Recombinant Non-Glycosylated Proteins Biosimilars Product Introduction
      • 7.6.4 Amgen Response to COVID-19 and Related Developments
    • 7.7 Samsung Biologics
      • 7.7.1 Samsung Biologics Business Overview
      • 7.7.2 Samsung Biologics Recombinant Non-Glycosylated Proteins Biosimilars Quarterly Revenue, 2020
      • 7.7.3 Samsung Biologics Recombinant Non-Glycosylated Proteins Biosimilars Product Introduction
      • 7.7.4 Samsung Biologics Response to COVID-19 and Related Developments
    • 7.8 Mylan
      • 7.8.1 Mylan Business Overview
      • 7.8.2 Mylan Recombinant Non-Glycosylated Proteins Biosimilars Quarterly Revenue, 2020
      • 7.8.3 Mylan Recombinant Non-Glycosylated Proteins Biosimilars Product Introduction
      • 7.8.4 Mylan Response to COVID-19 and Related Developments
    • 7.9 Dr. Reddy's Laboratories
      • 7.9.1 Dr. Reddy's Laboratories Business Overview
      • 7.9.2 Dr. Reddy's Laboratories Recombinant Non-Glycosylated Proteins Biosimilars Quarterly Revenue, 2020
      • 7.9.3 Dr. Reddy's Laboratories Recombinant Non-Glycosylated Proteins Biosimilars Product Introduction
      • 7.9.4 Dr. Reddy's Laboratories Response to COVID-19 and Related Developments
    • 7.10 Stada Arzneimittel AG
      • 7.10.1 Stada Arzneimittel AG Business Overview
      • 7.10.2 Stada Arzneimittel AG Recombinant Non-Glycosylated Proteins Biosimilars Quarterly Revenue, 2020
      • 7.10.3 Stada Arzneimittel AG Recombinant Non-Glycosylated Proteins Biosimilars Product Introduction
      • 7.10.4 Stada Arzneimittel AG Response to COVID-19 and Related Developments

    8 Key Findings

      9 Appendix

      • 9.1 About US

      This report covers market size and forecasts of Recombinant Non-Glycosylated Proteins Biosimilars, including the following market information:
      Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)

      Key market players
      Major competitors identified in this market include Sandoz, Pfizer, Teva Pahrmaceutical, Celltrion, Biocon, Amgen, Samsung Biologics, Mylan, Dr. Reddy's Laboratories, Stada Arzneimittel AG, etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      Insulin
      rHGH
      Interferon

      Based on the Application:
      Oncology
      Chronic Diseases
      Autoimmune Diseases
      Blood Disorders
      Growth Hormone Deficiency
      Infectious Diseases
      Other Diseases

      Buy now